Glial Cell Line Derived Neurotrophic Factor Market
Global Glial Cell Line Derived Neurotrophic Factor Market Size, Share, and Trend Analysis Report, By Type (GSK-812, LAUR-301, TW-002, AMT-090, and Others), By Application (Amyotrophic Lateral Sclerosis, Brain Ischemia, Parkinson's Disease, Retinal Degeneration, and Others), Forecast (2022-2028) Update Available - Forecast 2024-2030
The global glial cell line-derived neurotrophic factor market is expected to rise at a considerable CAGR (2022-2028). The GDNF gene encodes a protein called glial cell-derived neurotrophic factor (GDNF). GDNF is a tiny protein that supports the survival of a variety of neuronal types and connects with GFR receptors, notably GFR1. The rising incidence of Parkinson's disease (PD) throughout the world is a primary factor driving the market's rise. According to the Parkinson Foundation, nearly one million people in the US have Parkinson's disease, with that number expected to rise to 1.2 million by 2030.
Impact of COVID-19 Pandemic on Global Glial Cell Line Derived Neurotrophic Factor Market
The COVID-19 pandemic had impacted the global glial cell line-derived neurotrophic factor market industry significantly owning to the lockdown in most of the nations to control the spread of the virus. the influence of COVID-19 on the worldwide glial cell line-derived neurotrophic factor market from both a global and regional viewpoint. The influence of these elements on the market is highlighted via opportunities and difficulties. The market's inherent elements are the drivers and restrictions, while the market's extrinsic aspects are the opportunities and challenges.
Segmental Outlook
The global glial cell line-derived neurotrophic factor market is segmented based on type and application. Based on the type, the market is segmented into GSK-812, LAUR-301, TW-002, AMT-090. Based on the application, the market is sub-segmented into Amyotrophic Lateral Sclerosis, Brain ischemia, Parkinson’s disease, Retinal Degeneration. Based on type, GSK-812, LAUR-301, TW-002, AMT-090 are expected to hold the major share in the market.
Global Glial Cell Line Derived Neurotrophic Factor Market Share by Application, 2021 (%)
The Parkinson’s Disease Segment is Expected to Hold Prominent Share in the Global Glial Cell Line Derived Neurotrophic Factor Market
Parkinson’s disease holds the major share in the global glial cell line-derived neurotrophic factor market in the application segment. Glial cell-derived neurotrophic factor has a strong neuroprotective impact on mesencephalic dopamine neurons, which are slowly damaged in Parkinson's disease. This intrastriatal factor could be used as a Parkinson's disease treatment. The striatum, septum, and thalamus all produce glial cell line-derived neurotrophic factor spontaneously, although its consequences in the adult brain remain unknown. According to the Parkinson Foundation, there are nearly one million persons in the US who have Parkinson's disease, with the number expected to rise to 1.2 million by 2030.
Regional Outlooks
The global glial cell line derived neurotrophic factor market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). Among the regions, the Asia Pacific is anticipated to hold a significant share in the market followed by North America, and then Europe.
Global Glial Cell Line Derived Neurotrophic Factor Market Growth, by Region 2022-2028
The Asia-Pacific Region Expected to Hold Prominent Share in the Global Glial Cell Line Derived Neurotrophic Factor Market
Asia-Pacific region is expected to hold in the glial cell line derived neurotrophic factor market owing to the increasing cases of Parkinson’s disease. Men have 1.5 times the prevalence of Parkinson's disease as compared to women. As a result, with rising prevalence of this disease, the demand for glial cell line derived neurotrophic factors for treatment also increases, propelling the global glial cell line derived neurotrophic factor market.
Market Players Outlook
The major companies serving the global glial cell line-derived neurotrophic factor market include GlaxoSmithKline plc, Treeway BV, and others are among the market's leading participants. To stay competitive in the market, industry players are using a variety of tactics such as mergers and acquisitions, regional expansion, partnerships and collaborations, and new product releases to contribute substantially to market growth. Additionally, approximately 60,000 Americans are diagnosed with Parkinson's disease each year, and over 10 million people worldwide suffer from the disease. Furthermore, while Parkinson's disease worsens with age, an estimated 4% of people with the disease are diagnosed before the age of 50.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global glial cell line-derived neurotrophic factor market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Impact of COVID-19 on the Global Glial Cell Line Derived Neurotrophic Factor
- Recovery Scenario of Global Glial Cell Line Derived Neurotrophic Factor Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. GlaxoSmithKline Plc
3.1.1.1. Overview
3.1.1.2. Financial Analysis
3.1.1.3. SWOT Analysis
3.1.1.4. Recent Developments
3.1.2. Treeway BV
3.1.2.1. Overview
3.1.2.2. Financial Analysis
3.1.2.3. SWOT Analysis
3.1.2.4. Recent Developments
3.1.3. UniQure NV
3.1.3.1. Overview
3.1.3.2. Financial Analysis
3.1.3.3. SWOT Analysis
3.1.3.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players
4. Market Segmentation
4.1. Global Glial Cell Line Derived Neurotrophic Factor Market by Type
4.1.1. GSK-812
4.1.2. LAUR-301
4.1.3. TW-002
4.1.4. AMT-090
4.2. Global Glial Cell Line Derived Neurotrophic Factor Market by Application
4.2.1. Amyotrophic Lateral Sclerosis
4.2.2. Brain Ischemia
4.2.3. Parkinson's disease
4.2.4. Retinal Degeneration
5. Regional Analysis
5.1. North America
5.1.1. US
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. GlaxoSmithKline Plc
6.2. Treeway BV
6.3. UniQure NV
6.4. Merck & Co. Inc.
6.5. AbbVie Inc.
6.6. Mylan NV
1. GLOBAL GLIAL CELL DERIVED NEUROTROPHIC FACTOR MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL GSK-812 GLIAL CELL DERIVED NEUROTROPHIC FACTOR MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL LAUR-301 GLIAL CELL DERIVED NEUROTROPHIC FACTOR MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL GLIAL CELL DERIVED NEUROTROPHIC FACTOR MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
5. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS GLIAL CELL DERIVED NEUROTROPHIC FACTOR MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL BRAIN ISCHEMIA GLIAL CELL DERIVED NEUROTROPHIC FACTOR MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL GLIAL CELL DERIVED NEUROTROPHIC FACTOR MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
8. NORTH AMERICAN GLIAL CELL DERIVED NEUROTROPHIC FACTOR MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
9. NORTH AMERICAN GLIAL CELL DERIVED NEUROTROPHIC FACTOR MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
10. NORTH AMERICAN GLIAL CELL DERIVED NEUROTROPHIC FACTOR MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
11. EUROPEAN GLIAL CELL DERIVED NEUROTROPHIC FACTOR MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
12. EUROPEAN GLIAL CELL DERIVED NEUROTROPHIC FACTOR MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
13. EUROPEAN GLIAL CELL DERIVED NEUROTROPHIC FACTOR MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
14. ASIA-PACIFIC GLIAL CELL DERIVED NEUROTROPHIC FACTOR MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
15. ASIA-PACIFIC GLIAL CELL DERIVED NEUROTROPHIC FACTOR MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
16. ASIA-PACIFIC GLIAL CELL DERIVED NEUROTROPHIC FACTOR MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
17. REST OF THE WORLD GLIAL CELL DERIVED NEUROTROPHIC FACTOR MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
18. REST OF THE WORLD GLIAL CELL DERIVED NEUROTROPHIC FACTOR MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
19. REST OF THE WORLD GLIAL CELL DERIVED NEUROTROPHIC FACTOR MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL GLIAL CELL DERIVED NEUROTROPHIC FACTOR MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL GLIAL CELL DERIVED NEUROTROPHIC FACTOR MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL GLIAL CELL-DERIVED NEUROTROPHIC FACTOR MARKET, 2022-2028 (%)
4. GLOBAL GLIAL CELL-DERIVED NEUROTROPHIC FACTOR MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5. GLOBAL GSK-812 GLIAL CELL-DERIVED NEUROTROPHIC FACTOR MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL LAUR-301 GLIAL CELL-DERIVED NEUROTROPHIC FACTOR MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL GLIAL CELL-DERIVED NEUROTROPHIC FACTOR MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
8. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS GLIAL CELL-DERIVED NEUROTROPHIC FACTOR MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL BRAIN ISCHEMIA GLIAL CELL-DERIVED NEUROTROPHIC FACTOR MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL GLIAL CELL-DERIVED NEUROTROPHIC FACTOR MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. US GLIAL CELL DERIVED NEUROTROPHIC FACTOR MARKET SIZE, 2021-2028 ($ MILLION)
12. CANADA GLIAL CELL DERIVED NEUROTROPHIC FACTOR MARKET SIZE, 2021-2028 ($ MILLION)
13. UK GLIAL CELL DERIVED NEUROTROPHIC FACTOR MARKET SIZE, 2021-2028 ($ MILLION)
14. FRANCE GLIAL CELL DERIVED NEUROTROPHIC FACTOR MARKET SIZE, 2021-2028 ($ MILLION)
15. GERMANY GLIAL CELL-DERIVED NEUROTROPHIC FACTOR MARKET SIZE, 2021-2028 ($ MILLION)
16. ITALY GLIAL CELL-DERIVED NEUROTROPHIC FACTOR MARKET SIZE, 2021-2028 ($ MILLION)
17. SPAIN GLIAL CELL-DERIVED NEUROTROPHIC FACTOR MARKET SIZE, 2021-2028 ($ MILLION)
18. REST OF EUROPE GLIAL CELL-DERIVED NEUROTROPHIC FACTOR MARKET SIZE, 2021-2028 ($ MILLION)
19. INDIA GLIAL CELL-DERIVED NEUROTROPHIC FACTOR MARKET SIZE, 2021-2028 ($ MILLION)
20. CHINA GLIAL CELL-DERIVED NEUROTROPHIC FACTOR MARKET SIZE, 2021-2028 ($ MILLION)
21. JAPAN GLIAL CELL-DERIVED NEUROTROPHIC FACTOR MARKET SIZE, 2021-2028 ($ MILLION)
22. SOUTH KOREA GLIAL CELL-DERIVED NEUROTROPHIC FACTOR MARKET SIZE, 2021-2028 ($ MILLION)
23. REST OF ASIA-PACIFIC GLIAL CELL-DERIVED NEUROTROPHIC FACTOR MARKET SIZE, 2021-2028 ($ MILLION)
24. REST OF THE WORLD GLIAL CELL DERIVED NEUROTROPHIC FACTOR MARKET SIZE, 2021-2028 ($ MILLION)
